Patients Stopping Weight-Loss Injections Regain Weight Four Times Faster Than People Using Diet and Exercise

Fresh analysis suggests that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds far faster than those who end conventional diet and exercise plans.

Research printed in a prominent medical journal shows that while overweight individuals often shed about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Users buying these treatments must be aware of the risk of fast weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.

Such speed of regain means a reversion to original mass within about 18 months.

Comparing Treatments

The research, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.

Scientists emphasize that individuals who shed pounds through diet and exercise generally experience a more gradual weight regain—approximately 0.1 kg a month—post-intervention.

Explaining the Fast Regain

Doctors suggest the way of the jabs is key to understanding the heightened regain.

These medications mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating a significant risk."

A Chronic Issue?

The NHS advise the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.

Professionals argue that, considering the likelihood of relapse, the treatment might need to be ongoing.

This view is echoed by drug manufacturers, who say that the results "underscore the chronic nature of obesity," similar to managing conditions like high blood pressure.

User Accounts

Users who have stopped the jabs explain a intense return of appetite.

"It felt as if something activating and I was suddenly ravenous," described one woman.

The struggle is exacerbated if patients have not adopted lasting dietary or behavioural changes during treatment.

Widespread Interest

Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.

• Use is greater among females compared to men.
• The 40s and 50s age group shows the greatest level of interest.
• Many access the drugs through private prescriptions rather than the NHS.

In conclusion, researchers emphasize that while these medications are potent agents for weight loss, they are not a standalone cure and maintained weight loss hinges on combined behavioural changes.